Huseyin Naci and colleagues call for improvements in the regulatory standards for licensing, reimbursing, and adopting new preventive drugs to ensure that treatments for type 2 diabetes really benefit patients (BMJ)
Diabetes News
Tag: Type 2 Diabetes
Impact of insulin initiation on glycaemic variability and glucose profiles in a primary healthcare Type 2 diabetes cohort: analysis of continuous glucose monitoring data from the INITIATION study
Insulin initiation reduced hyperglycaemia but did not alter glycaemic variability in adults with Type 2 diabetes receiving maximum oral hypoglycaemic agents (Diabetic Medicine)
A prospective randomized controlled study of a virtual clinic integrating primary and specialist care for patients with Type 2 diabetes mellitus
The virtual clinic model explored in this study showed a clinically important improvement in glycaemic control. Although this improvement was not superior to that observed in the control participants, this might be attributable to the systemic impact of the virtual clinic on the practice as a whole (Diabetic Medicine)
Disparities in type 2 diabetes prevalence among ethnic minority groups resident in Europe
The risk of T2D among ethnic minority groups living in Europe compared to Europeans varies by geographical origin of the group: three to five times higher among South Asian, two to four times higher among Middle Eastern and North African, and two to three times higher among Sub-Saharan African origin (Internal and Emergency Medicine)
Behavioral Programs for Type 2 Diabetes Mellitus
Diabetes self-management education offering 10 or fewer hours of contact with delivery personnel provided little benefit. Behavioral programs seem to benefit persons with suboptimal or poor glycemic control more than those with good control (Annals of Internal Medicine)
Metabolic predictors of impaired glucose tolerance and type 2 diabetes in a predisposed population
In sum, genetically predisposed individuals for T2D with deteriorating glucose tolerance exhibit insulin resistance as well as beta-cell and signs of adipose tissue dysfunction, emphasizing the multifactorial pathophysiology in the development of IGT and T2D (BMC Endocrine Disorders)
A critical review of low-carbohydrate diets in people with Type 2 diabetes
Total energy intake remains the dietary predictor of body weight. A LCD appears no different from a high-carbohydrate diet in terms of metabolic markers and glycaemic control (Diabetic Medicine)
2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions
Our results support the use of AP at home as a safe and beneficial option for patients with type 1 diabetes. The HbA1c results are encouraging but preliminary (Lancet)
Helicobacter pylori infection associated with type 2 diabetic nephropathy in patients with dyspeptic symptoms
Diabetic nephropathy patients are more susceptible to H. pylori infection. Our data support an association between H. pylori infection and diabetic nephropathy (Diabetes Research and Clinical Practice)
Clinical factors that predict remission of diabetes after different bariatric surgical procedures: interdisciplinary group of bariatric surgery of Verona (G.I.C.O.V.)
Bariatric surgical procedures that modify the upper gastrointestinal tract anatomy (RYBP and SG) are more successful in producing weight loss and remission of T2D than those that simply restrict stomach capacity (LAGB). Younger age, short duration of diabetes and better glucose control confer higher probability of achieving remission of diabetes (Acta Diabetologica)
Effect of Roux-en-Y gastric bypass on the distribution and hormone expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes
Numerous alterations in the distribution of enteroendocrine cells and their expression of hormonal genes are seen after RYGB and include increased density of GLP-1-, PYY-, CCK-, GIP- and PC2-positive cells, reduced gene expression of GHRL, SCT and GIP and increased expression of GC (Diabetologia)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care (NEJM)
Sanofi Reports Positive Top-Line Results in Second Pivotal LixiLan Phase III Study
The fixed-ratio combination of insulin glargine 100 Units/mL and lixisenatide, a GLP-1 receptor agonist, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared with insulin glargine 100 Units/mL
Bariatric–metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial
Surgery is more effective than medical treatment for the long-term control of obese patients with type 2 diabetes and should be considered in the treatment algorithm of this disease. However, continued monitoring of glycaemic control is warranted because of potential relapse of hyperglycaemia (Lancet)
Diabetes (type 1 and type 2) in children and young people: diagnosis and management
The guideline recommends strict targets for blood glucose control to reduce the long-term risks associated with diabetes (NICE)
Statins and the Risk of Pancreatic Cancer in Type 2 Diabetic Patients – A Population-Based Cohort Study
Statin use may be associated with a reduced risk of pancreatic cancer in type 2 diabetic patients. More research is needed to clarify this association (International Journal of Cancer)
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial
Among overweight and obese participants with type 2 diabetes, use of subcutaneous liraglutide (3.0 mg) daily, compared with placebo, resulted in weight loss over 56 weeks. Further studies are needed to evaluate longer-term efficacy and safety (JAMA)
Comparison of basal insulin therapies regarding the risk of acute myocardial infarction in type 2 diabetic patients
In contrast to a former database study, no difference was observed for the risk of AMI between long-acting analog and NPH insulin in this study. Neither long-acting analog insulin nor premix insulin appears to be associated with AMI in patients with type 2 diabetes (Diabetes, Obesity and Metabolism)
A journey into a Mediterranean diet and type 2 diabetes: a systematic review with meta-analyses
The Mediterranean diet was associated with better glycaemic control and cardiovascular risk factors than control diets, including a lower fat diet, suggesting that it is suitable for the overall management of type 2 diabetes (BMJ Open)
Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes
Among patients with newly diagnosed T2DM, 22% remained under poor glycaemic control over 2 years, and 26% never received IT. Delay in IT by 1 year in conjunction with poor glycaemic control significantly increased the risk of MI, HF, stroke and composite CVE (Cardiovascular Diabetology)
- « Previous Page
- 1
- …
- 59
- 60
- 61
- 62
- 63
- …
- 65
- Next Page »
Glycosmedia is also available as an App: